In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including:
First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval
Adverse event identification and management
Generalized strategies to support patient adherence to TKIs
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify
Presenters:
Elizabeth Krueger, NP
Center for Thoracic Cancers
Mass General Brigham Cancer Institute
Boston, Massachusetts
Sam Vafadar, DHSc, PA-C
Physician Associate
Department of Thoracic Oncology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podden och tillhörande omslagsbild på den här sidan tillhör
Decera Clinical Education. Innehållet i podden är skapat av Decera Clinical Education och inte av,
eller tillsammans med, Poddtoppen.